Speakers

Sandra Cuellar, PharmD, BCOP

University of Illinois Hospital & Health Sciences System
Chicago, Illinois

Sandra Cuellar, PharmD, BCOP, is a Clinical Associate Professor in the Department of Pharmacy Practice at the University of Illinois at Chicago (UIC) College of Pharmacy. Dr. Cuellar has been active in the field of hematology/oncology for 17 years. She is the Coordinator and Clinical Associate Professor for Oncology Therapeutics. Dr. Cuellar received her Bachelor of Liberal Arts from Augustana College in Rock Island, Illinois, followed by her PharmD from the University of Illinois at Chicago College of Pharmacy. She then completed a Pharmacy Practice Residency at University of Kentucky Chandler Medical Center. Following her residency, she completed a specialty oncology residency at MD Anderson Cancer Center in Houston, Texas. She currently is the Clinical Pharmacist in the Outpatient Cancer Center, Director of the Oncology Specialty Residency Program, and Vice-Chair of IRB at UIC. Dr. Cuellar is an Editor-at-Large for the Journal of Hematology Oncology Pharmacy and is involved in research, consulting and publications in the field of hematology/oncology. She has given multiple national and international presentations on cardio-oncology, supportive care, and oncology therapeutics. In addition, Dr. Cuellar serves as an ASHP oncology surveyor and continues to serve on multiple committees for Hematology Oncology Pharmacy Association.

Back to top

Rita Nanda, MD

Director, Breast Oncology Program
The University of Chicago Medicine
Chicago, Illinois

Rita Nanda, MD, is an Associate Professor of Medicine and Director of Breast Oncology at The University of Chicago. Dr. Nanda earned her undergraduate degree in Chemical Engineering from the Massachusetts Institute of Technology and her Medical Degree from The University of Chicago, Pritzker School of Medicine. She subsequently completed her Residency in Internal Medicine and her Fellowship in Hematology/Oncology at The University of Chicago.

Dr. Nanda’s research interests include identifying novel treatments for the management of breast cancer, particularly triple-negative disease. She leads The University of Chicago’s clinical and translational breast cancer research efforts, and serves as a Principal Investigator for the Translational Breast Cancer Research Consortium (TBCRC) and the ISPY2 Clinical Trial Network. She is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, and the Society for Immunotherapy of Cancer.

Dr. Nanda has authored numerous scientific publications and book chapters, including one of the first reports of immune checkpoint inhibitor therapy for triple-negative breast cancer. She has been invited to present her research at national and international conferences. In recognition of her leadership and research contributions in developing novel strategies for women with breast cancer, she was awarded the 2014 NCI Cancer Clinical Investigator Team Leadership Award. She has been selected to serve on a number of international committees, including the Breast Immuno-Oncology (BIO) Taskforce of the National Cancer Institute (NCI) Breast Cancer Steering Committee (BCSC), the Breast International Group-North American Breast Cancer (BIG-NABCG) Taskforce on Immunotherapy for Breast Cancer, and the BIG-NABCG Taskforce on Tailoring Immunotherapy for Triple-Negative Breast Cancer.

Dr. Nanda’s research has been funded by The NIH, The Department of Defense Breast Cancer Research Program, The Doris Duke Charitable Foundation, The Susan G. Komen Foundation, and The Metastatic Breast Cancer Network. She currently serves as a co-PI on The University of Chicago’s Interdisciplinary Cancer Health Disparities P20 SPORE and a Breast Cancer Research Foundation Grant investigating the role of androgen receptor (AR) blockade in AR positive triple-negative breast cancer.

Back to top